Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed Memorial Day 05-22 16:00:00 EDT

297.45

-3.06

-1.02%

盘后297.45

+0.000.00%

19:29 EDT

High303.33	Low294.99	Vol681.31K
Open299.12	D1 Closing300.51	Amplitude2.78%
Mkt Cap39.69B	Tradable Cap37.52B	Total Shares133.43M
T/O202.45M	T/O Rate0.54%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":297.45,"timestamp":1779480000000,"preClose":300.51,"halted":0,"volume":681308,"hourTrading":{"tag":"盘后","latestPrice":297.45,"preClose":297.45,"latestTime":"19:29 EDT","volume":58661,"amount":17448767.7688,"timestamp":1779492581248,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010182689427972454,"floatShares":126154848,"shares":133427910,"eps":4.0295005,"marketStatus":"Closed Memorial Day","change":-3.06,"latestTime":"05-22 16:00:00 EDT","open":299.12,"high":303.3299,"low":294.99,"amount":202452600.30164,"amplitude":0.027752,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.0295005,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":300.51,"preHourTrading":{"tag":"盘前","latestPrice":299.01,"preClose":300.51,"latestTime":"09:29 EDT","volume":382,"amount":114482.51207999999,"timestamp":1779456599999,"change":-1.5,"changeRate":-0.004992,"amplitude":0.012763},"postHourTrading":{"tag":"盘后","latestPrice":297.45,"preClose":297.45,"latestTime":"19:29 EDT","volume":58661,"amount":17448767.7688,"timestamp":1779492581248,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8028714009930136,"impliedVol":0.3421,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2637207943","title":"Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2637207943","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637207943?lang=en_us&edition=fundamental","pubTime":"2026-05-23 22:28","pubTimestamp":1779546485,"startTime":"0","endTime":"0","summary":"What recent price moves tell you about Alnylam Pharmaceuticals (ALNY)\nAlnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock down over the past month and past 3 months but slightly higher over the past year.\nSee our latest analysis for Alnylam Pharmaceuticals.\nAt a share price of US$297.45, Alnylam’s short term share price return has been weak, with the stock down year to date. Longer term total shareholder returns over 3 and 5...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-mixed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALNY","LU0109394709.USD","BK4585","BK4139","LU0114720955.EUR","BK4548","LU0889565916.HKD","LU0320765992.SGD","LU0882574055.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636281039","title":"J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636281039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636281039?lang=en_us&edition=fundamental","pubTime":"2026-05-20 17:16","pubTimestamp":1779268608,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst maintained a Buy rating on Alnylam Pharma today and set a price target of $420.00. In a report released on May 6, Barclays also...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636162018","title":"U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv","url":"https://stock-news.laohu8.com/highlight/detail?id=2636162018","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636162018?lang=en_us&edition=fundamental","pubTime":"2026-05-20 15:07","pubTimestamp":1779260842,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, VertivMay 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CAVA Gro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nL4N41X0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMZD","AMRX","CRWD","CRC","MIRM","BMRN","WHD","HD","CAVA","BRO","CHRW","CRWL","ALNY","GGLL","DVN","EOG","MVLL","FANG","CNCG","ELV","CVS","EBAY","LMRI","AMZU","MRVU","LRCU","INCY","EXP","KLAC","AMZN","DKS","APA","HALO","S","KEYS","MRVL","USAW.SI","INSM","LRCX","CNC","JAZZ","GOOGL","META","GGLS","HSY","IONS","AMZY","HUM","DRUG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636890914","title":"Alnylam Pharmaceuticals Inc : JP Morgan Resumes Coverage With Overweight Rating; Price Target $420","url":"https://stock-news.laohu8.com/highlight/detail?id=2636890914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636890914?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:01","pubTimestamp":1779253308,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41W0J3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","ALNY","LU0114720955.EUR","LU0109394709.USD","LU0882574055.USD","BK4588","BK4139","BK4548","BK4585","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636857627","title":"Alnylam Pharmaceuticals Initiated at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2636857627","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636857627?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:43","pubTimestamp":1779201780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 10:43 ET (14:43 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU0320765992.SGD","LU0882574055.USD","BK4588","LU0109394709.USD","LU0114720955.EUR","BK4139","ALNY","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856426","title":"Alnylam publishes 2025 corporate responsibility report","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856426","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856426?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:30","pubTimestamp":1779193843,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals announced the publication of its 2025 Corporate Responsibility Report, outlining a Scope 1 and Scope 2 GHG emissions reduction framework through 2030, backed by an independent third-party review of its GHG inventory and methodology.Patient access initiatives cited include a new Patient Advisory Council, nearly doubling the size of its Case Management team, nearly doubling the size of its Access & Reimbursement teams, and the release of quantitative and qualitative metrics tied to its access strategy.Philanthropy disclosures include a two-year USD 2 million commitment under the Alnylam Challengers program to support Care Navigators in underserved Boston communities via partnerships with Boston Children’s Hospital, Boston Medical Center, and Whittier Street Health Center.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL2ZlnWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","LU0320765992.SGD","LU0114720955.EUR","LU0882574055.USD","LU0889565916.HKD","BK4548","LU0109394709.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636323830","title":"Alnylam Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Target Price $380","url":"https://stock-news.laohu8.com/highlight/detail?id=2636323830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636323830?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:30","pubTimestamp":1779186632,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41V1LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU0109394709.USD","LU0882574055.USD","BK4585","LU0114720955.EUR","ALNY","BK4139","BK4548","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636351728","title":"U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2636351728","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636351728?lang=en_us&edition=fundamental","pubTime":"2026-05-19 15:56","pubTimestamp":1779177409,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron TechnologyMay 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nL4N41W0N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XYZY","MU","FFIV","GPN","ALNY","CYTK","BFRI","SJM","ELF","AMT","CTXR","LU2272731865.HKD","CSX","HCA","COSW","XE","ALT","D","ECL","BBIO","AMH","PGNY","FRT","HOG","MUD","ELMT","ADC","BMRN","MULL","TILE","AGYS","APO","MUU","AMAT","INVH","HUN","ACM","REGN","CRWD","CRWL","COST","THG","GOSS","BC","XYZG","COTG","AGL","BXSL","XYZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009292","title":"Alnylam initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009292?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:25","pubTimestamp":1779135959,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Alnylam (ALNY) with a Buy rating and $380 price target The expanded launch of Amvuttra for ATTR-CM has “no doubt been im...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","ALNY","BK4139","LU0889565916.HKD","LU0114720955.EUR","BK4588","LU0320765992.SGD","BK4585","LU0882574055.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635874431","title":"Alnylam’s New Phase 1 ALN-4915 Trial: Early Safety Data in Focus for ALNY Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635874431","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635874431?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:35","pubTimestamp":1778776515,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study “A Study to Evaluate ALN-4915 in Adult Healt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylams-new-phase-1-aln-4915-trial-early-safety-data-in-focus-for-alny-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylams-new-phase-1-aln-4915-trial-early-safety-data-in-focus-for-alny-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","BK4548","LU0114720955.EUR","BK4588","ALN","ALNY","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4585","LU0882574055.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635736064","title":"PLTR, KTOS, ALNY: 3 High P/E Stocks with 40%+ Upside Potential in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635736064","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635736064?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:26","pubTimestamp":1778685965,"startTime":"0","endTime":"0","summary":"Using the TipRanks Highest P/E Ratio Stocks tool, we identified three companies with high price-to-earnings (P/E) ratios and more than 40% upside p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/pltr-ktos-alny-3-high-p-e-stocks-with-40-upside-potential-in-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/pltr-ktos-alny-3-high-p-e-stocks-with-40-upside-potential-in-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9P08.USD","BK4547","KTOS","LU0320765992.SGD","ALNY","BK4603","PTIR","BK4585","KTUP","LU1861559042.SGD","PLTA","LU0114720955.EUR","BK4543","PLOO","PLTG","PLTI","BK4548","PLTY","PLT","BK4187","IE00BZ9MQY76.HKD","IE00B894F039.SGD","PLTU","IE00B19Z9Z06.USD","LU0109394709.USD","PLTR","PLYY","BK4588","LU0882574055.USD","LU1861558580.USD","PLTZ","BK4023","BK4613","LU0889565916.HKD","PLTW","BK4139","PLTD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724467","title":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-05-12","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724467","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724467?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:45","pubTimestamp":1778611520,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-05-12Nasdaq 100 .NDXTop PerformersPercent ChangeInsmed Inc INSM.OQ+12.8%Vertex Pharmaceuticals Inc VRTX.OQ+3.3%Dexcom Inc DXCM.OQ+2.8%Intuitive Surgical Inc ISRG.OQ+2.7%Alnylam Pharmaceuticals Inc ALNY.OQ+2.6%Bottom PerformersPercent ChangeQualcomm Inc QCOM.OQ-12.8%Sandisk Corp SNDK.OQ-8.9%Intel Corp INTC.OQ-8.8%Western Digital Corp WDC.OQ-7.3%Strategy Inc MSTR.OQ-6.1%The Nasdaq 100 .NDX lost 444.90 points, or 1.52%, to 28,875.76 and recorded 4 new highs and 3 new lows. 42 stocks rose and 59 fell as declining issues outnumbered advancers by about a 1.4-to-1 ratio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P2XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0081259029.USD","LU1244550577.SGD","LU0256863811.USD","LU1989764664.SGD","BK4512","LU1035775433.USD","BK4532","SNDK","LU1868837300.USD","SG9999001176.SGD","LU2543165471.USD","MSOO","ISUL","ISRG","LU0114720955.EUR","LU1061106388.HKD","IE00BMPRXN33.USD","SG9999001424.SGD","LU1868836591.USD","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU1778281490.HKD","LU1989764748.USD","LU0234570918.USD","QCMU","LU2433249047.HKD","LU1119994496.HKD","LU1815336760.USD","SMI3.UK","LU2023250843.SGD","LU2462157665.USD","LU1951198990.SGD","IE00BGHQDM52.EUR","LU1804176565.USD","LU0444973449.USD","SMST","LU0266013472.USD","MSTP","LU2106854487.HKD","3LMI.UK","IE00BSNM7G36.USD","IE000M9KFDE8.USD","BK4527","BK4535","LU2148611432.USD","BK4516","LU0444971666.USD","BK4551","LU1917777945.USD","BK4504","BK4612","MSDD","LU0882574055.USD","IE00BMPRXR70.SGD","IE00B19Z8X17.USD","LU1585245621.USD","LU0354030511.USD","LU1069347547.HKD","LU2362541273.HKD","LU1674673691.USD","LU1923623000.USD","LU0006061336.USD","BK4550","LU2112291526.USD","SG9999015945.SGD","SNXX","SG9999015986.USD","LU0823416689.USD","MSII","BK4585","LU1069344957.HKD","3SMI.UK","BK4602","LU2089985449.USD","BK4548","LINT","BK4581","INSM","BK4534","LU1951200564.SGD","SG9999001176.USD","IE0002141913.USD","LU0321505439.SGD","GB00BDT5M118.USD","LU1366192091.USD","BK4588","LU1923622614.USD","LU2324357040.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","09399","BK4579","WDCX","IE00B19Z9505.USD","IE00B2B36J28.USD","MSTU","IE00B19Z3B42.SGD","LU0963586101.USD","LU2237438978.USD","BK4082","LU0321505868.SGD","BK4170","IE00BYQQ9H92.USD","IE00B19Z9Z06.USD","LU2362540622.SGD","LU0079474960.USD","LU1974910355.USD","WDC","LU1823568750.SGD","LU1868837136.USD","LU1023059063.AUD","LU1084165304.USD","LU2211815571.USD","LU0868494708.USD","IE00B4R5TH58.HKD","IE00B19Z3581.USD","LU2265009873.SGD","BK4141","LU0823434740.USD","07399","IMST","MSTY","LU2210149790.SGD","LU0053671581.USD","BK4596","INTW","LU0122379950.USD","NDAQ","SG9999015978.USD","BK4561","QCOM","BK4567","BK4573","MSTX","APED","LU0289739699.SGD","BK4600","LU1046421795.USD","LU0957808578.USD","VRTX","LU1093756325.SGD","BK4554","LU1674673428.USD","LU2247934214.USD","LU2125909593.SGD","LU0889565916.HKD","LU1868836914.USD","BK4604","MSTY.UK","IE00BFXG0V08.USD","LU1868836757.USD","MSTR","LU0238689110.USD","09799","IE0002270589.USD","LU0274383776.USD","MST","DXCM","BK4139","IE00BVYPNQ40.USD","LU2063271972.USD","LU1093756168.USD","BK4595","BK4023","LU0476273544.USD","BK4529","LU2236285917.USD","IE00BJT1NW94.SGD","BK4515","LU1323610961.USD","LU0354030438.USD","LU1235294995.USD","LU2417539215.USD","MSST","LU1057294990.SGD","BK4575","IE0009355771.USD","LU0061475181.USD","SGXZ57979304.SGD","LU0058720904.USD","SG9999002224.SGD","WNTR","LU1261432733.SGD","INTC","LU0390134368.USD","LU2456880835.USD","LU0097036916.USD","BK4598","MSTK","LU2095319765.USD","IE00BVYPNP33.GBP","LU2023250504.SGD","LU0320765992.SGD","SG9999015952.SGD","IE00B19Z8W00.USD","IE00B19Z9P08.USD","LU0109394709.USD","LU0432979614.USD","07799","BK4543","LU2362541513.USD","LU0942090050.USD","LU1035773651.USD","SG9999002232.USD","MSTZ","ALNY","QCMD","IE00BZ9MQY76.HKD","LU1642822529.SGD","LMI3.UK","SG9999013999.USD","LU0054578231.USD","QCML","04335","LU0868494617.USD","BK4605","IE00B894F039.SGD","LU1244550221.USD","IE00B5TLWC47.USD","LU1496350502.SGD","LU1983299246.USD","BK4533","LU2125909247.SGD","LU2210150020.SGD","LU1244550494.USD","MSTW","LU0823434583.USD","MTYY","LU2931357623.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292715","title":"Alnylam announces new analyses from HELIOS-B study of vutrisiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292715?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:53","pubTimestamp":1778579627,"startTime":"0","endTime":"0","summary":"Alnylam (ALNY) announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-announces-new-analyses-from-helios-b-study-of-vutrisiran-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-announces-new-analyses-from-helios-b-study-of-vutrisiran-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","LU0882574055.USD","BK4548","LU0114720955.EUR","BK4588","BK4585","LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629782","title":"Alnylam says HELIOS-B analysis shows vutrisiran benefit across ATTR-CM patient groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629782","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634629782?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:30","pubTimestamp":1778567427,"startTime":"0","endTime":"0","summary":"Alnylam highlighted new analyses from HELIOS-B Phase 3 trial of vutrisiran in ATTR-CM, with results already presented at Heart Failure 2026.Analyses showed clinical benefit remained consistent across harder-to-treat patient groups, including those with atrial fibrillation, low systolic blood pressure, or higher overall disease burden, supporting positioning as a first-line option.Benefits also held up in patients using common background therapies, including ATTR stabilizers or standard heart-failure drugs, strengthening case for broad real-world use.Separate pooled safety analysis across more than 25,000 patient-years of exposure for vutrisiran and patisiran found low rates of vitamin A deficiency-related eye events, comparable to placebo, easing a key monitoring concern for TTR-lowering therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbQNkzC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","LU0320765992.SGD","LU0114720955.EUR","LU0882574055.USD","LU0889565916.HKD","BK4548","LU0109394709.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634262312","title":"New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across Attr-Cm Patient Populations, Including Patients With a High Disease Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2634262312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634262312?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:30","pubTimestamp":1778567400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA5LCTDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0109394709.USD","LU0882574055.USD","ALNY","BK4588","BK4548","LU0114720955.EUR","BK4585","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144843","title":"Alnylam to webcast investor conference presentations at BofA, Goldman Sachs healthcare events","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144843","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144843?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:03","pubTimestamp":1778155393,"startTime":"0","endTime":"0","summary":"Alnylam to present at BofA Securities Healthcare Conference on May 13, 2026 at 10:40 a.m. PT in Las Vegas.Management also scheduled to present at Goldman Sachs Annual Healthcare Conference on June 9, 2026 at 11:20 a.m. ET in Miami.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on May 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLb0qYKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0882574055.USD","BK4139","LU2237438978.USD","LU2471134952.CNY","ALNY","LU0648000940.SGD","LU0096364046.USD","LU0234572021.USD","LU0683600562.USD","LU2237443549.SGD","LU1201861249.SGD","LU1280957306.USD","LU1880398554.USD","LU0321505439.SGD","LU0321505868.SGD","BK4550","LU0310800965.SGD","IE0004091025.USD","GS","LU0868494617.USD","LU2129689431.USD","LU0256863811.USD","GSX","LU1496350171.SGD","LU1363072403.SGD","LU1366192091.USD","LU0052756011.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU0320765489.SGD","LU1880398471.USD","LU0320765992.SGD","BK4588","LU1804176565.USD","LU2237443622.USD","LU1496350502.SGD","LU0477156797.USD","LU0742534661.SGD","IE0002270589.USD","BK4504","LU2237443382.USD","LU2237443978.SGD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU0306806265.USD","LU1868836591.USD","BAC","LU0130517989.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633032152","title":"Tenaya Therapeutics Q1 net loss widens, misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633032152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633032152?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:35","pubTimestamp":1778099753,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Q1 net loss widens, misses analyst expectationsOverviewUS biotech for heart disease posted Q1 net loss and operating loss, both missing analyst expectationsOperating expenses for Q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1CY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4539","LU0889565916.HKD","LU0114720955.EUR","TNYA","ALNY","BK4588","BK4548","LU0882574055.USD","BK4139","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633212151","title":"Vir Biotechnology Q1 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633212151","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633212151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:12","pubTimestamp":1778098371,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q1 net loss widensOverviewUS biopharma firm's Q1 net loss widened yr/yr as revenue turned negativeCompany ended Q1 with $809.3 mln in cash and investments, excluding Astellas payment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4548","BK4535","ALNY","BK4585","BK4588","BK4139","LU0114720955.EUR","BK4568","LU0882574055.USD","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633912334","title":"Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633912334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633912334?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:11","pubTimestamp":1777979460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 07:11 ET (11:11 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632539979","title":"Alnylam presents new vutrisiran analyses at Heart Failure congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2632539979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632539979?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:30","pubTimestamp":1777897842,"startTime":"0","endTime":"0","summary":"Alnylam will present new analyses on vutrisiran for transthyretin amyloidosis with cardiomyopathy at Heart Failure 2026, European Society of Cardiology congress, May 9-12, 2026, in Barcelona.Presentations draw from Phase 3 HELIOS-B, including subgroup efficacy and pharmacodynamic transthyretin knockdown results, with additional safety analyses focused on vitamin-A-related outcomes.Conference sessions featuring the data are scheduled May 10-12, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbvQWW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","LU0882574055.USD","BK4548","LU0114720955.EUR","BK4588","BK4585","LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0365},{"period":"1month","weight":-0.0423},{"period":"3month","weight":-0.1152},{"period":"6month","weight":-0.3184},{"period":"1year","weight":0.0292},{"period":"ytd","weight":-0.252}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.037597},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}